Officials will use participation as evidence that the process was inclusive and broadly supported. That claim provides procedural cover for inaction, allowing officials to present incremental adjustments as stakeholder-supported reform. The Delphi studies will be weaponised as a durable rhetorical shield against renewed scrutiny. There are options.
Stakeholders must act to protect their voice in response to the risk of a manufactured consensus
May 7, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Novo Nordisk backs care for rural health professionals in southern NSW
August 19, 2026 - - Latest News -
Opportunity #3 - finally deliver on the repeated claims of patient-centricity
August 19, 2026 - - Latest News -
Departmental restructure formally splits medicines financing from pharmacy services
August 19, 2026 - - Latest News -
Wesfarmers Health evolves its loyalty program with new Pulse Rewards
August 19, 2026 - -
CSL absorbs loss in reset year as investors back its plasma-led recovery
August 18, 2026 - - Latest News -
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - - Latest News -
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - - Latest News

